![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: SEC14L5 |
Gene summary for SEC14L5 |
![]() |
Gene information | Species | Human | Gene symbol | SEC14L5 | Gene ID | 9717 |
Gene name | SEC14 like lipid binding 5 | |
Gene Alias | PRELID4B | |
Cytomap | 16p13.3 | |
Gene Type | protein-coding | GO ID | GO:0003674 | UniProtAcc | O43304 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
9717 | SEC14L5 | HCC2 | Human | Liver | HCC | 2.08e-08 | 6.18e-01 | 0.5341 |
9717 | SEC14L5 | HCC5 | Human | Liver | HCC | 3.27e-06 | 5.17e-01 | 0.4932 |
9717 | SEC14L5 | S016 | Human | Liver | HCC | 8.53e-05 | 1.57e-01 | 0.2243 |
Page: 1 |
![]() |
Tissue | Expression Dynamics | Abbreviation |
Liver | ![]() | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
SEC14L5 | SNV | Missense_Mutation | c.11G>T | p.Arg4Ile | p.R4I | O43304 | protein_coding | deleterious(0) | benign(0.053) | TCGA-EO-A22X-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unspecific | Carboplatin | Complete Response | |
SEC14L5 | SNV | Missense_Mutation | novel | c.1159G>A | p.Gly387Arg | p.G387R | O43304 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-EY-A1G7-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
SEC14L5 | SNV | Missense_Mutation | rs369229826 | c.1828N>A | p.Val610Ile | p.V610I | O43304 | protein_coding | tolerated(0.52) | benign(0) | TCGA-EY-A1GU-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
SEC14L5 | SNV | Missense_Mutation | novel | c.269A>C | p.Glu90Ala | p.E90A | O43304 | protein_coding | tolerated(0.12) | benign(0.14) | TCGA-FI-A2D5-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | carboplatinum | PD |
SEC14L5 | SNV | Missense_Mutation | novel | c.629G>T | p.Ser210Ile | p.S210I | O43304 | protein_coding | tolerated(0.08) | benign(0.001) | TCGA-FI-A2D5-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | carboplatinum | PD |
SEC14L5 | SNV | Missense_Mutation | novel | c.1500G>T | p.Glu500Asp | p.E500D | O43304 | protein_coding | tolerated(0.16) | benign(0.104) | TCGA-FI-A2D5-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | carboplatinum | PD |
SEC14L5 | insertion | Frame_Shift_Ins | rs764657044 | c.1856_1857insC | p.Ser622GlnfsTer31 | p.S622Qfs*31 | O43304 | protein_coding | TCGA-AX-A3G3-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD | ||
SEC14L5 | insertion | Frame_Shift_Ins | novel | c.1427dupG | p.Glu477ArgfsTer5 | p.E477Rfs*5 | O43304 | protein_coding | TCGA-DF-A2KY-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | carboplatin | SD | ||
SEC14L5 | SNV | Missense_Mutation | c.1052N>A | p.Leu351Gln | p.L351Q | O43304 | protein_coding | deleterious(0) | probably_damaging(0.989) | TCGA-CC-A7IK-01 | Liver | liver hepatocellular carcinoma | Male | <65 | III/IV | Unknown | Unknown | PD | |
SEC14L5 | SNV | Missense_Mutation | c.1376N>C | p.Gly459Ala | p.G459A | O43304 | protein_coding | deleterious(0) | probably_damaging(0.949) | TCGA-44-3918-01 | Lung | lung adenocarcinoma | Female | <65 | I/II | Chemotherapy | carboplatin | SD |
Page: 1 2 3 4 5 6 7 8 9 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |